GABY Inc's Mankind Dispensary Celebrates One Million Shoppers with a Huge Customer Appreciation Event March 24-27, 2022
The four-day event celebrates Mankind's notable milestone, and brings the San Diego cannabis community together at one of the city's most popular dispensaries.
SAN DIEGO, CA / ACCESSWIRE / March 23, 2022 / GABY Inc. ("GABY" or the "Company") (CSE:GABY) (OTCQB:GABLF), a California consolidator of cannabis dispensaries and the parent company of San Diego's Mankind Dispensary ("Mankind"), is proud to announce the dispensary has served 1 million customers since first opening its doors in 2016. The dispensary, which serves tens-of-thousands of customers per month, is a cornerstone of the California cannabis community, and has garnered a stellar reputation as the bridge between traditional and new consumer in part due to its "no glass barriers" approach to cannabis, with a fully self-serve model and extremely knowledgeable retail cannabis consultants.
The event, lovingly dubbed the "One Million Stoned" celebration will bring the San Diego cannabis community together with experienced shoppers and cannabis first-timers for a series of education sessions, and customer give-backs.
The event includes:
One-on-one cannabis consultations with Mankind's top-rated cannabis geniuses.
Joint rolling masterclass with any purchase
Cannabis glassware cleaning from San Diego's Fresh Sesh®
"Mankind has been a pillar of the California cannabis community since its founding." said GABY Inc Founder and CEO Margot Micallef. "Customers from every walk of life visit the store each day - from tie-dyed seniors, to high-dose millennials, medical patients, first timers, wellness warriors and everything in-between. I'm immensely proud of the work our team does to meet the disparate needs of such a diverse clientele. I'm impressed how they can engage with experienced consumers and how patient and helpful they are with new consumers. I look forward to celebrating with the entire Mankind family."
An inside look at Mankind's hands-on cannabis flower wall,
which has more than 90 strains available to smell, see, and touch before buying. (Photo - Scott Saw)
In addition to the customer-giveback and cannabis education events, Mankind will also be celebrating the California cannabis cultivators that have helped establish the dispensary as one of the top destinations for cannabis in the state. The One Million Customer event will feature a highly curated menu from brands such as SOG Army (known for their Dutch "sea of green" cultivation technique), Cannabis Cup darlings Cannabiotix, Blueprint (which was hailed as "The most exciting summer launch of 2021 by LA Weekly's Jimi Devine), San Diego locals CLSICs, and more.
"The best part of my job is connecting the California cannabis consumers with the cultivators and brands that continuously set the bar higher and higher with new growing methods, extraction processes, and innovative breeding techniques." said Mankind's Purchasing Manager Zac Larson. "We've got a really special lineup planned for this event, and I can't wait to celebrate this milestone with the people that have helped put Mankind on the map."
Mankind License Number: C10-0000494-LIC. 21+ Recreational. 18+ Medical.
About GABY Inc.
GABY Inc. is a California-focused retail consolidator and the owner of Mankind Dispensary, one of the oldest licensed dispensaries in California. Mankind is a well-known, and highly respected dispensary with deep roots in the California cannabis community operating in San Diego, California. GABY curates and sells a diverse portfolio of products, including its own proprietary brands, Lulu's™ and Kind Republic™ through Mankind, manufactures Kind Republic, and distributes all its proprietary brands through its wholly owned subsidiary, GABY Manufacturing. A pioneer in the industry with a multi-vertical retail foundation, and a strong management team with experience in retail, consolidation, and cannabis, GABY is poised to grow its retail operations both organically and through acquisition.
GABY's shares trade on the Canadian Securities Exchange ("CSE") under the symbol "GABY" and on the OTCQB under the symbol "GABLF". For more information on GABY, visit GABYInc.com
Senior Communications Manager
Margot Micallef, Founder & CEO
or Investor Relations at IR@GABYinc.com
Disclaimer and Forward-Looking Information
The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to, the Company's future business strategy, including its plans to expand organically and through future acquisitions and the Company's anticipated benefits from its engagement with Hybrid Financial. Although GABY believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because GABY can give no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Without limitation, these risks and uncertainties include: the severity of the COVID-19 pandemic; risks associated with the cannabis industry in general; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; the size of the medical-use and adult-use cannabis market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; failure to comply with certain regulations; and departure of key management personnel or inability to attract and retain talent. GABY undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Each of Mankind and GABY Manufacturing, are subsidiaries of GABY and hold a cannabis license in the State of California. Readers are cautioned that unlike in Canada which has Federal 032320-F legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), in the United States ("U.S."), cannabis is largely regulated at the State level. Cannabis is legal in the State of California; however, cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY's subsidiaries are conducted in a manner consistent with the State law of California, as applicable, and are in compliance with regulatory and licensing requirements applicable in the State of California, respectively. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiary of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiary. Any such proceedings brought against GABY, or its subsidiary may materially adversely affect the Company's operations and financial performance generally in the U.S. market specifically
SOURCE: GABY Inc.
View source version on accesswire.com: